AbbVie news in 2026: 33 dated events
The latest AbbVie event on this page is dated Oct 30, 2026. tradingview.com reported: AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82.
Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn
Get AbbVie's live signals in Claude or ChatGPT, or by API
What changed at AbbVie this week? Use Autobound signals for abbvie.com.- Dated events
- 33
- Last 90 days
- 25
- Latest
- Oct 30, 2026
Source: Autobound Signal API · 110 signals tracked for AbbVie · updated
News · latest 10
Latest AbbVie news
Showing 10 of 33 dated events. The Signal API returns all of them.
Get them with one API call- AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82AbbVie reported third-quarter 2026 revenue of $17.404 billion, an increase of 10.3% year over year.
- AbbVie Reports Third-Quarter 2026 Financial ResultsWith Apogee Therapeutics
- AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple MyelomaAbbVie submitted a Biologics License Application to the FDA for its multiple myeloma drug candidate etentamig.
- U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseAbbVie announced that the U.S. FDA approved a subcutaneous induction regimen for SKYRIZI for adults with moderately to severely active Crohn's disease.
- AbbVie unveils positive Phase III results for lutikizumabAbbVie published positive Phase III results evaluating the efficacy and safety of its investigational drug lutikizumab.
- AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO ReadoutsAbbVie reported Phase 2a trial data for its investigational dual-targeting Crohn's disease therapy ABBV-466.
- AbbVie's subcutaneous risankizumab meets Phase III AFFIRM endpointsAbbVie reported Phase III trial results for its subcutaneous induction regimen of risankizumab (Skyrizi) in patients with Crohn's disease.
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCAbbVie is developing telisotuzumab adizutecan (Temab-A; ABBV-400), an investigational antibody-drug conjugate for CRC and NSCLC which received two FDA Breakthrough Therapy Designations.
- AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly...AbbVie and Genmab announced positive topline results from a Phase 3 trial of their jointly developed drug, epcoritamab, in combination with R-CHOP, for treating newly diagnosed diffuse large B-cell lymphoma (DLBCL).
- AbbVie (NYSE:ABBV) Wins FDA Approval for Parkinson's Pill Juvmo as Dermatology Congress OpensWith Cerevel Therapeutics
Showing 10 of 33 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track AbbVie with the Signal API
One POST /v1/companies/enrich call with abbvie.com returns AbbVie news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about AbbVie news
What is the latest news on AbbVie?
What is going on with AbbVie?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .